Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma

24 Jan 2022

Abstract excerpt

Although hotspot mutations in isocitrate dehydrogenase (IDH) genes are associated with favorable clinical outcomes in glioma, CDKN2A/B homozygous deletion has been identified as an independent predicator of poor prognosis. Accordingly, the 2021 edition of the World Health Organization (WHO) classification of tumors of the central nervous system (CNS) has adopted this molecular feature by upgrading IDH-mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments
Share to Radiomics and Machine Learning in Medical Imaging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35203456
DOI: 10.3390/biomedicines10020246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant GliomaPMID 35203456Read ↗

Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.Semantic proximity Read ↗

CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature ReviewSemantic proximity Read ↗

CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.Semantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.Semantic proximity Read ↗

IDH mutant high-grade gliomasSemantic proximity Read ↗

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.Semantic proximity Read ↗

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.